Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Xu Y; Villalona-Calero MAAnn Oncol 2002[Dec]; 13 (12): 1841-51Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.|*Drug Resistance, Neoplasm[MESH]|*Maximum Tolerated Dose[MESH]|*Topoisomerase I Inhibitors[MESH]|Animals[MESH]|Apoptosis/drug effects/physiology[MESH]|Camptothecin/adverse effects/*analogs & derivatives/*pharmacology/therapeutic use[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Administration Schedule[MESH]|Female[MESH]|Humans[MESH]|Irinotecan[MESH]|Male[MESH]|NF-kappa B/*drug effects/metabolism[MESH]|Neoplasms/diagnosis/*drug therapy[MESH]|Risk Assessment[MESH]|Sensitivity and Specificity[MESH] |